Disability and rehabilitation · 2026
Effect of fully immersive virtual reality on daily pain, functional mobility, and health-related quality of life in pediatric sickle cell disease: a single-blinded randomized clinical trial.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hassan Bakri Afnan Ahmed, Algabbani Maha F, Farrag Ahmed, Elsayed Walaa, Rezk Mohsen Z A, Bindawas Saad M, Alhusaini Adel A, Shaheen Afaf A M
Аннотация
PURPOSE: Sickle cell disease (SCD) causes abnormal hemoglobin, chronic pain, anemia, and organ damage. Virtual reality (VR) is a non-pharmacological tool for pain management; its effectiveness in SCD remains underexplored. This study evaluates the effect of an adjunctive fully immersive VR on daily pain and its impact on functional mobility and health-related quality of life (HRQOL) in children with SCD.
MATERIALS AND METHODS: In this single-blinded, randomized controlled trial, forty children (8-18 years) were randomized to VR + usual care (n = 20) or usual care alone (n = 20). The VR group received six 40-minute sessions over three weeks. Outcomes included pain (Numeric Rating Scale), mobility (Timed Up and Go test), and HRQOL (Pediatric Quality of Life Inventory). ClinicalTrials.gov (Identifier: NCT05952817).
RESULTS: The intervention group showed significant pain reduction, improved mobility, and enhanced HRQOL compared to controls over five weeks (pain: η2 = 0.28, p < 0.001; mobility: η2 = 0.18, p < 0.001; HRQOL: η2 = 0.08-0.68, p < 0.001). VR was safe and well-tolerated.
CONCLUSION: Adjunctive VR with usual care significantly reduces pain, improves mobility, and enhances HRQOL in children with SCD, supporting its feasibility and safety.
MATERIALS AND METHODS: In this single-blinded, randomized controlled trial, forty children (8-18 years) were randomized to VR + usual care (n = 20) or usual care alone (n = 20). The VR group received six 40-minute sessions over three weeks. Outcomes included pain (Numeric Rating Scale), mobility (Timed Up and Go test), and HRQOL (Pediatric Quality of Life Inventory). ClinicalTrials.gov (Identifier: NCT05952817).
RESULTS: The intervention group showed significant pain reduction, improved mobility, and enhanced HRQOL compared to controls over five weeks (pain: η2 = 0.28, p < 0.001; mobility: η2 = 0.18, p < 0.001; HRQOL: η2 = 0.08-0.68, p < 0.001). VR was safe and well-tolerated.
CONCLUSION: Adjunctive VR with usual care significantly reduces pain, improves mobility, and enhances HRQOL in children with SCD, supporting its feasibility and safety.